Pulmonary drugs market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to fuel the market growth include a rise in the prevalence of chronic diseases such as bronchitis, tuberculosis, and chronic obstructive pulmonary disease and a rise in tobacco smoking. Pulmonary drug delivery systems deliver drugs to the lung for the treatment of respiratory tract diseases. This route is preferred broadly owing to the non-invasive technique, high blood circulation, large surface area for absorption, and permeability rate. Recent advancements in pulmonary drug delivery devices and methods, rise in gastrointestinal upset, respiratory diseases, and minimum dose requirement are the driving factors that will accelerate the growth of the market during the forecast period.
Moreover, rising incidences of chronic respiratory diseases will surge the demand for pulmonary drugs. As per the Global Asthma Report 2018, around 339 million people are affected by Asthma globally. The significant increase in the targeted patient pool will promote the demand for pulmonary drugs. Furthermore, R&D associated with the pulmonary drugs coupled with government and non-government initiatives will create lucrative opportunities for the market in the coming years, which in turn are expected to boost the market growth during the forecast period. For instance, CDC’s National Asthma Control Program (NACP) provides funds for educating asthma-affected patients. Such initiatives are likely to raise awareness about asthma, which will increase the adoption of pulmonary drugs in the treatment of chronic obstructive pulmonary disease (COPD) and asthma, leading to the growth of the global pulmonary drugs market.
To Request a Sample of our Report on Pulmonary Drugs Market: https://www.omrglobal.com/request-sample/pulmonary-drugs-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape:GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Novartis AG, Merck & Co., Inc., and AstraZeneca plc.
Pulmonary Drugs Market Report by Segment
By Drug Class
- Beta-2 Agonists
- Anticholinergic Agents
- Oral and Inhaled Corticosteroids
- Anti-leukotrienes
- Antihistamines
- Monoclonal Antibodies
- Combination Drugs
- Others
By Indication
- Asthma
- COPD (Chronic Obstructive Pulmonary Disease
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
A full Report of Pulmonary Drugs Market is Available at: https://www.omrglobal.com/industry-reports/pulmonary-drugs-market
Pulmonary Drugs Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
